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SCIENTIFIC OPINION 
Scientific Opinion on Flavouring Group Evaluation 401 (FGE.401): γ-
Glutamyl-valyl-glycine from chemical group 34
1
 
EFSA Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids 
(CEF)
2,3
  
European Food Safety Authority (EFSA), Parma, Italy 
ABSTRACT  
The Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids of the European Food Safety 
Authority was requested to carry out a safety assessment of one flavouring substance, γ-glutamyl-valyl-glycine 
[FL-no: 17.038], in the Flavouring Group Evaluation 401 (FGE.401), in accordance with the Commission 
Regulation (EC) No 1331/2008. There is no safety concern with respect to genotoxicity for the flavouring 
substance. It has been demonstrated that the flavouring substance, which is a tripeptide, will be hydrolysed to the 
three amino acids L-glutamic acid, L-valine and glycine. As the human consumption of these three endogenous 
amino acids through food is orders of magnitude higher than the anticipated levels of exposure from their use as 
flavouring substances, the Panel concluded that γ-glutamyl-valyl-glycine [FL-no: 17.038] would be of no safety 
concern at its estimated level of intake as flavouring substance. The specifications for γ-glutamyl-valyl-glycine 
[FL-no: 17.038] are considered adequate according to Commission Regulation (EC) no 1334/2008. 
© European Food Safety Authority, 2014 
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SUMMARY  
Following a request from the European Commission, the European Food Safety Authority (EFSA) 
asked the Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids (CEF Panel) 
to deliver a scientific opinion to the Commission on the implications for human health of chemically 
defined flavouring substances used in or on foodstuffs in the Member States. In particular, EFSA was 
requested to carry out a safety assessment of one flavouring substance (candidate substance) in the 
Flavouring Group Evaluation 401 (FGE.401) in accordance with Commission Regulation (EC) no. 
1334/2008.  
The candidate substance, γ-glutamyl-valyl-glycine [FL-no: 17.038], is a synthetic substance; however, 
it has been identified as a natural component in vegetable and animal materials and has been 
quantitated in some unprocessed and processed food. 
According to the applicant, γ-glutamyl-valyl-glycine [FL-no: 17.038] is intended to be used to modify 
and balance the total flavour bringing out the middle to afternote and adds brothy, creamy flavours 
similar to that of well-cooked stew.  
The dietary exposure to the candidate substance from use as a flavouring substance is calculated to be 
92 μg/kg bw/day in a 60 kg adult and 231 μg/kg bw/day in a 15 kg three-year old child. The Panel is 
aware that the flavouring substance is not intended to be used in the food categories specifically 
intended for infants and young children, however, they may also consume food from the general food 
categories flavoured with the candidate substance. Nevertheless, as the safety assessment of the 
substance is based on exposure to the separate amino acids, the Panel considers this to be of no safety 
concern. 
There was no indication of a genotoxic potential of the candidate substance in the bacteria reversion 
mutation assays, in an in vitro chromosome aberration assay or in an in vivo micronucleus test.  
Since it can be assumed that the candidate substance γ-glutamyl-valyl-glycine [FL-no: 17.038] is 
rapidly hydrolysed to its individual amino acids after consumption, the Panel based its risk assessment 
on the hydrolysis products, the three individual amino acids, L-glutamic acid (evaluated by the 
JECFA, JECFA no 1420), L-valine [FL-no: 17.028] (evaluated by the EFSA in FGE.26Rev1) and 
glycine [FL-no: 17.034] (evaluated by the JECFA, JECFA no 1421 and considered by EFSA in 
FGE.79). The human exposure to these three endogenous amino acids through food is orders of 
magnitude higher than the anticipated levels of exposure from their use as flavouring substances. 
Therefore, these three substances were not taken through the Procedure and the Panel concluded that 
the substances were not of safety concern at their estimated levels of intake as flavouring substances. 
The specifications for [FL-no: 17.038] are considered adequate according to Commission Regulation 
(EC) no 1334/2008.   
Based on the above considerations, the candidate substance γ-glutamyl-valyl-glycine [FL-no: 17.038] 
is not considered to be of safety concern at its estimated level of intake as flavouring substance.  
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BACKGROUND AS PROVIDED BY THE EUROPEAN COMMISSION 
The use of flavourings is regulated under Regulation (EC) No 1334/2008
4
 of the European Parliament 
and Council of 16 December 2008 on flavourings and certain food ingredients with flavouring 
properties for use in and on foods. On the basis of article 9(a) of this Regulation, an evaluation and 
approval are required for flavouring substances. 
Regulation (EC) No 1331/2008 shall apply for the evaluation and approval of flavouring substances. 
The Commission has received from the company Aijnomoto Co.Inc. an application from the 
authorisation of a new flavouring substance. 
In order for the Commission to be able to consider its inclusion in the Union list of flavourings and 
source materials (Annex I of Regulation (EC) No 1334/2008), EFSA should carry out a safety 
assessment of this substance. 
TERMS OF REFERENCE AS PROVIDED BY THE COMMISSION 
The European Commission requests the European Food Safety Authority EFSA to carry out a safety 
assessment on γ-glutamyl-valyl-glycine as a flavouring substance in accordance with Regulation (EC) 
No 1331/2008 establishing a common authorisation procedure for food additives, food enzymes and 
food flavourings. 
                                                     
4  Regulation (EC) No 1334/2008 of the European Parliament and of the Council of 16 December 2008 on flavourings and 
certain food ingredients with flavouring properties for use in and on foods and amending Council Regulation (EEC) No 
1601/91, Regulations (EC) No 2232/96 and (EC) No 110/2008 and Directive 2000/13/EC. OJ L 354, 31.12.2008, p. 34-50. 
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ASSESSMENT 
1. Identification of the Substance 
The name of the flavouring substance (candidate substance) is γ-glutamyl-valyl-glycine, FLAVIS 
number [FL-no: 17.038], CAS number 38837-70-6. 
H
N
N
H
OH
O
HO
O O
ONH2
 
2. Existing Authorisations and Evaluations 
The candidate substance γ-glutamyl-valyl-glycine [FL-no: 17.038] has been evaluated by the JECFA 
(as a structural class I compound (Cramer et al, 1978) with the JECFA no 2123) to be of no safety 
concern [at current estimated dietary exposure] using an NOAEL level of a JECFA-approved 
dipeptide as support (JECFA, 2012) and has FEMA GRAS status (FEMA 4709). The substance has 
not been in use previously in the European Union. 
3. Manufacturing Process 
3.1. Source Material 
The candidate substance is chemically synthesised. Information on the source materials (starting 
chemicals, intermediates, reagents and process solvents) has been provided. This information has been 
classified as confidential by the applicant, but is available to the EFSA.  
3.1.1. Genetically Modified Organism 
The candidate substance is not produced by or from genetically modified organisms (GMOs). 
3.2. Production Process 
The principles of the synthesis have been provided. Information on the production process is 
confidential, but is available to the EFSA. 
4. Physical/chemical properties and specifications 
4.1. Chemical Name 
IUPAC name: L-γ-glutamyl-L-valyl-glycine 
CAS name: Glycine, L-γ-glutamyl-L-valyl-. 
4.2. Identification Numbers 
CAS-number: 38837-70-6 
FLAVIS-number: [FL-no: 17.038] 
JECFA-number: 2123 
FEMA GRAS: 4709. 
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4.3. Chemical and Structural Formula, Molecular Weight 
 
H
N
N
H
OH
O
HO
O O
ONH2
 
Chemical formula: C12H21N3O6 
Molecular weight: 303.31Da. 
4.4. Physical Form 
Off-white powder. 
4.5. Organoleptic characteristics 
Odourless. 
4.6. Solubility Data 
Water: very soluble: 133 g/l 
Ethanol: slightly soluble 
Insoluble in non-polar solvents. 
4.7. Identity Analysis 
IR, UV, 
1
H-and 
13
C NMR, MS. 
4.8. Purity/Minimum Assay Value 
Purity of commercial preparation is > 95 % (Flavour Industry, 2014).   
4.9. Impurities 
The main impurities found using HPLC analysis were L-γ-Glutamyl-L-Valyl-L-Valyl-Glycine (2.0 %) 
along with L-α-glutamyl-L-valyl-glycine (α-Glu-Val-Gly) plus its cyclisation product  
 5-oxo-L-prolyl-L-valyl-glycine (PCA-Val-Gly) (the two together amounting to 0.7 %).  Other, related 
small peptides were detected and the sum of all peptide impurities was about 4 %.  Residual solvents 
were tested for by GC and the results were ethyl acetate < 50 mg/kg, methanol < 30 mg/kg, 
tetrahydrofuran < 10 mg/kg and toluene < 10 mg/kg (Flavour Industry, 2014). 
4.10. Physical Parameters 
Melting point: 225 - 228 °C. 
4.11. Configuration 
The candidate substance has two asymmetrical centres. The configuration is (S)-γ-glutamyl-(S)-valyl-
glycine. 
4.12. Stability and Decomposition Products 
A 12 months stability study was conducted under 25 ˚C / 60 % RH and 40 ˚C / 75 % RH conditions. 
No changes were observed regarding content and enantiomeric composition; however, α-Glu-Val-Gly, 
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one of the major impurities (see Section 4.9) was cyclised into PCA-Val-Gly (another of the impurities 
found in the original commercial preparations) in a temperature and time dependent manner. The 
applicant proposed the expiration period to be two years for the material of commerce. 
4.13. Interaction with Food Components 
This was not considered by the applicant. 
4.14. Particle Size 
The particle size is 1 - 100 μm. 
CONCLUSION ON SPECIFICATIONS 
The information provided on composition and specification of the flavouring substance is considered 
sufficient by the Panel.               
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Table 1:  Specification Summary of the Substances in the Flavouring Group Evaluation 401 
FL-no EU Register 
name 
Structural 
formula 
JECFA no 
FEMA no 
CoE no 
CAS no 
EINECS no 
Phys.form 
Mol.formula 
Mol.weight 
Impurities 
 
Solubility(a) 
Solubility in 
ethanol(b) 
Others   
Boiling point, °C(c) 
Melting point, °C 
ID test 
Assay minimum 
Refrac. 
Index(d) 
Spec.gravity(e) 
Specification 
comments 
17.038 γ-Glutamyl-
valyl-
glycine 
* 2123 
4709 
- 
38837-70-6 
- 
 
Solid 
C12H21N3O6 
303.31  
5-oxo-L-prolyl-L-valyl-glycine 
(PCA-Val-Gly) and 
L-α-glutamyl-L-valyl-glycine (α-
Glu-Val-Gly) 0.7 % 
L-γ-glutamyl-L-valyl-L-valyl-
glycine 2.0 % 
 
Residual solvents:  
ethyl acetate < 50 mg/kg,  
methanol < 30 mg/kg, 
tetrahydrofuran < 10 mg/kg  
and toluene < 10 mg/kg  
Very soluble 
Slightly soluble 
- 
- 
225-228 °C 
IR, UV, NMR, MS 
> 95 % 
n.a. 
n.a. 
 
 
(a) Solubility in water, if not otherwise stated. 
(b) Solubility in 95 % ethanol, if not otherwise stated. 
(c) At 1013.25 hPa, if not otherwise stated. 
(d) At 20°C, if not otherwise stated. 
(e) At 25°C, if not otherwise stated.  
 
* 
H
N
N
H
OH
O
HO
O O
ONH2
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5. Structural/Metabolic Similarity to Substances in an Existing FGE (Appendix B) 
The candidate substance γ-glutamyl-valyl-glycine [FL-no: 17.038] has a number of structural elements 
common to chemical group 34 listed in Annex I to Commission Regulation (EC) No 1565/2000
5
.  
Chemical group 34 contains the amino acids. Two EFSA opinions, FGE.26Rev1 (EFSA, 2008a) and 
FGE.79 (EFSA, 2008b) consider the amino acids present in the Union list. Based on the results of in 
vitro hydrolysis experiments involving a microsomal fraction and a homogenate of human small 
intestinal mucosa, the Panel concluded that the flavouring substance can be anticipated to be readily 
hydrolysed upon consumption. Therefore, its safety assessment can be based on the individual amino 
acids in chemical group 34 and EFSA opinions FGE.26Rev1 and FGE.79. 
6. Exposure Assessment (Appendix C) 
All data necessary for the calculation of normal and maximum occurrence levels for refined sub 
categories of foods and beverages are reported in Appendix C. 
6.1. Concentration in Processed and Non-processed Foods from Natural Occurrence 
The candidate substance γ-glutamyl-valyl-glycine [FL-no: 17.038] is a synthetic substance. It has been 
identified as a natural component in vegetable and animal materials and has been quantitated by 
LC/MS/MS in several food sources such as beer (0.09 - 0.18 mg/kg), cheese (0.35 - 0.59 mg/kg), fish 
sauce 0.36 - 11.14 mg/kg), soy sauce (1.34 - 5.78 mg/kg) and scallops (0.08 - 0.77 mg/kg) (Flavour 
Industry, 2013). The exposure scenarios include the estimated intake from such natural sources, 
which, however, is low as compared to the normal and maximum intake as a flavour (Appendix C).  
6.2. Non-food Sources of Exposure 
The Panel has no information of any non-food sources of exposure to the candidate substances. 
However, it could conceivably be used to modify the bitterness of pharmaceuticals that contain bitter 
components. This is not anticipated at this stage (Flavour Industry, 2014). 
6.3. Chronic Dietary Exposure 
The exposure estimate to be used in the safety assessment of the candidate substance is the Added 
Portions Exposure Technique (APET) approach defined in the EFSA scientific opinion “Guidance on 
the data required for the risk assessment of flavourings to be used in or on foods”6.  
The chronic APET will be calculated both for adults and children and the highest value among these 
will be used as the exposure estimate to be compared to the Threshold of Toxicological Concern 
(TTC) value in the Procedure. 
The highest chronic exposure is 231 µg/kg body weight (bw)/day derived from the scenario of a 15 kg 
three year old child consuming one portion of category 14.1 (Non-alcoholic (“soft”) beverages) and 
one portion of category 12.5 (Soups and broths). This intake will result in a chronic APET
7
 of 3465 
μg/child per day (231 μg/kg bw per day for a 15 kg child) (for calculation of the chronic APET, see 
Appendix C). 
 
                                                     
5  Commission Regulation (EC) No 1565/2000 of 18 July 2000 laying down the measures necessary for the adoption of an 
 evaluation programme in application of Regulation (EC) No 2232/96 of the European Parliament and of the Council.  
 OJ L 180, 19.7.2000, p. 8-16. 
6  EFSA Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids; Guidance on the data required for the 
 risk assessment of flavourings. EFSA Journal 2010; 8(6):1623. [38pp.]. doi:10.2093/j.efsa.2010.1623. 
7  Excluding sub-categories 13.4, 14.2.1, 14.2.2, 14.2.3 and 14.2.4. Standard portion sizes for children are obtained by 
 multiplying the adult standard portion sizes by a factor of 0.63. 
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Table 2:  APET – Chronic Dietary Exposure 
APET  
Added
(a)
  
(µg/kg bw/day) 
Other dietary sources
(b)
 
(µg/kg bw/day) 
Combined
(c)
  
(µg/kg bw/day) 
Use level Normal Maximum Average Maximum Normal Maximum 
Adults
(d) 92 n.a. 0 n.a 92 n.a 
Children
(e) 231 n.a. 0 n.a. 231 n.a. 
(Infants)
(f) The exposure to infants is currently under consideration in the EFSA exposure working 
group 
n.a. not applicable: the chronic APET calculation is based on the combined normal occurrence level. 
(a) APET Added is calculated on the basis of the amount of flavour added to a specific food category. 
(b) APET Other Dietary Sources is calculated based on the natural occurrence of the flavour in a specified food category. 
(c) APET Combined is calculated based on the combined amount of added flavour and naturally occurring flavour in a 
specified food category. 
(d) For the adult APET calculation a 60 kg person is considered representative. 
(e) For the child APET calculation a 3-year old child with a 15 kg bw is considered representative 
(f) For the infant (0 - 12 months) (and young children, 12 - 36 months) APET calculation a 12 months child with a 10 kg 
bw is considered representative. 
Despite the fact that the substance is not intended to be used in food categories specifically intended 
for infants and young children (food category 13.2a - 13.2h), they will also consume food from the 
general food categories which may contain the substance. However, because the safety assessment of 
the substance is based on exposure to the separate amino acids, the Panel considers this to be of no 
safety concern. 
6.4. Acute Dietary Exposure 
The highest acute dietary exposure is 1260 µg/kg bw derived from the scenario of a 15 kg three year 
old child consuming three portions (3 x 200 x 0.63 = 378 g) of category 12.5 (soups and broths) which 
contain the maximum concentration of [FL-no: 17.038] (see Appendix C). 
Table 3:  APET – Acute Dietary Exposure 
FL-no:  
APET Added  
(µg/kg bw) 
APET Other dietary 
sources (µg/kg bw) 
APET Combined  
(µg/kg bw) 
Use level Normal Maximum Average Maximum Normal Maximum 
Adults n.a. 500 n.a. 0 n.a. 500 
Children n.a. 1260 n.a. 0 n.a. 1260 
(Infants) 
The exposure to infants is currently under consideration in the EFSA exposure working 
group 
 
6.5. Cumulative Dietary Exposure (Appendix B) 
Structurally and metabolically related flavouring substances  
γ-Glutamyl-valyl-glycine is a tripeptide which readily hydrolyses into three amino acids, L-glutamic 
acid, L-valine and glycine in the homogenate of human small intestinal mucosa and in the microsomal 
fraction from human small intestinal mucosa. L-glutamic acid, L-valine and glycine are all three 
macronutrients, which are normal components of protein.  
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7. Genotoxicity (Appendix D) 
Structure alerts  
No structure alerts have been identified by the methods of Ashby and Tennant (Ashby and Tenant, 
1991) and Benigni et al. (Benigni et al., 2008). 
7.1. Genotoxicity Studies 
7.1.1. In vitro 
Bacterial reverse mutation assay 
In order to examine the mutagenic potential of γ-glutamyl-valyl-glycine [FL-no: 17.038], a reverse 
mutation assay was conducted in Salmonella typhimurium TA100, TA1535, TA98 and TA1537, and 
Escherichia coli WP2 uvrA with and without metabolic activation by the pre-incubation method. 
Water for injection was used as the vehicle for the test article (Oguma, 2010). The GLP study was 
conducted according to OECD Guideline 471.  
A preliminary experiment was conducted to determine the concentration levels to be used in the main 
experiment. All strains were exposed to concentrations between 19.5 and 5000 μg/plate. Based on 
these results the minimum concentration which showed growth inhibition was selected as the 
maximum concentration for the main test. The main test was conducted with six concentrations 
between 39.1 and 1250 μg/plate for  S. typhimurium TA1537 without metabolic activation, while in 
the presence of metabolic activation the concentrations were between 156 and 5000 μg/plate. For S. 
typhimurium TA98, TA100, TA1535, and E. coli WP2 uvrA with or without metabolic activation the 
concentrations tested were between 313 to 5000 μg/plate. The test was conducted twice using the same 
concentrations. 
Precipitation on the plate and coloration by the test article in the test systems were not observed at any 
dose levels with or without metabolic activation. 
In the observation of bacteria using a stereoscopic microscope, growth inhibition was observed at 
1250 μg/plate and above for S. typhimurium TA1537 without metabolic activation, and at 5000 
μg/plate for S. typhimurium TA1537 with metabolic activation. 
In the main experiments it was not observed any increase nor a dose related response in the number of 
revertant colonies compared to negative controls in any test system with or without metabolic 
activation. The positive control compounds for each tester strain showed the expected mutagenic 
activity, indicating that the study was conducted properly. 
It was concluded that γ-glutamyl-valyl-glycine [FL-no: 17.038] did not induce gene mutations in 
bacteria, under the conditions employed. 
Chromosome aberration test 
A chromosome aberration study was conducted using cultured Chinese hamster lung fibroblast 
(CHL/IU) cells to examine whether γ-glutamyl-valyl-glycine [FL-no: 17.038] has the potential to 
induce chromosome aberrations (Sono, 2010). The GLP study was conducted according to OECD 
Guideline 473. 
Short-term treatment (5 + 18 hours, with and without S9-mix) and continuous treatment (24 and 48 
hours, without S9-mix) methods were used. Based on the results of the cell-growth inhibition test, the 
study was conducted at three concentrations (775, 1550 and 3100 μg/mL). No cytotoxic effects were 
observed at the three concentrations used, while cell-growth inhibition exceeding 50 % was observed 
above 3100 μg/mL selected as the highest concentration. At all concentrations and conditions applied, 
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the frequencies of structural and numerical chromosomal aberration were comparable with the current 
negative control and were within historical control values.  
Thus, γ-glutamyl-valyl-glycine [FL-no: 17.038] did not show any potential to induce structural or 
numerical (polyploidy) chromosome aberrations under the conditions of this study. 
7.1.2. In vivo 
Mouse micronucleus test  
In order to examine whether γ-glutamyl-valyl-glycine [FL-no: 17.038] has clastogenic potential, a 
micronucleus study was conducted in Crlj:CD1(ICR)SPF mice (Ishii, 2010). The GLP study was 
conducted according to OECD Guideline 474. 
[FL-no: 17.038] was administered to the animals twice orally at an approximately 24-hour interval at 
500, 1000 or 2000 mg/kg bw/day and bone marrows smear specimens were prepared at approximately 
24 hours after the second administration. A negative control group received water for injection twice 
and a positive control was treated with mitomycin C once at 1 mg/kg. 
In the test article administration groups, the proportion of MNPCE was 0.15 ± 0.06 % in the 500 
mg/kg/day group, 0.15 ± 0.04 % in the 1000 mg/kg/day group and 0.08 ± 0.03 % in the 2000 
mg/kg/day. In comparison between these values and the value of 0.09 ± 0.07 % in the negative control 
group, there was no statistically significant increase in any test article administration group and there 
were no dose-related changes. The proportion of PCE in 200 entire erythrocytes in each test article 
administration group did not show any statistically significant change when compared to the negative 
control group. In this study, exposure of bone marrow to the test article was not demonstrated; 
however, since examination was conducted up to the highest concentration of 2000 mg/kg/day, which 
was described in the toxicity study guidelines, and since there is no indication for genotoxicity from 
the in vitro data a substantiation of target tissue exposure is not required. The proportion of MNPCE in 
the negative and positive control groups were within the range of each background data of the test 
facility. 
In conclusion, γ-glutamyl-valyl-glycine [FL-no: 17.038] was judged to have no potential to induce 
structural or numerical (aneuploidy) chromosome aberrations in bone marrow of mice under the 
conditions of this study. 
7.2. Conclusion on genotoxicity  
There was no indication of genotoxicity in the bacterial reversion assays, in an in vitro assay or in an 
in vivo micronucleus test. Thus, there is no safety concern with respect to genotoxicity for the 
candidate substance. 
8. Absorption, Distribution, Metabolism and Elimination  
No data are available on absorption or distribution of the tripeptide. It is presumably absorbed by 
carrier-mediated metabolism, but no data are provided. 
The hydrolysis of the candidate substance γ-glutamyl-valyl-glycine [FL-no: 17.038] by various 
hydrolytic enzymes in (simulated) stomach and gut preparations was investigated in vitro in order to 
find out whether assessment of the candidate substance could be based on its hydrolysis products, the 
amino acids glycine, L-valine and L-glutamate; enzymes expected to be involved are (γ-glutamyl)-
peptidases (Flavour Industry, 2013). 
Hydrolysis in a simulated gastric fluid at pH 1.18 indicated that [FL-no: 17.038] is not hydrolysed by 
added porcine pepsin (Sigma P6887; 6.4 mg/ml: “2-fold concentrated”) during 6 hours at 37 oC. The 
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concentration of [FL-no: 17.038] was based on the expected concentration after oral consumption of 
[FL-no: 17.038]-containing food, 19 ppm or 62 µM (Flavour Industry, 2013). 
Hydrolysis in simulated intestinal fluid at pH 7.5 indicated that [FL-no: 17.038] was hydrolysed by 
added porcine pancreatine (Sigma P8096; 20 mg/ml: “2-fold concentrated”); after 6 hours, some 60 % 
had been hydrolysed at 37 
oC. The dipeptide γ-Glu-Val remained below detection but some 20 % was 
present as the Val-Gly dipeptide after 6 hours. The concentration of [FL-no: 17.038] was based on the 
presumed intestinal concentration after oral consumption of [FL-no: 17.038]-containing food, 15 µM 
(Flavour Industry, 2013). 
Hydrolysis by a microsomal fraction from human small intestinal mucosa (XenoTech Co.Ltd; a 
pooled preparation from male and female human mucosa) at pH 8.0 indicated that [FL-no: 17.038] 
was rapidly hydrolysed by the microsomal preparation (8 mg/ml microsomal protein); already after 10 
minutes, 97 % had been hydrolysed, while 74 % was identified as the Val-Gly dipeptide. After 15 
minutes, the tripeptide was below the level of detection, while the Val-Gly dipeptide started to 
decrease. After 60 minutes, 39 % was still present as the dipeptide Val-Gly; the remainder presumably 
is in the form of the individual amino acids.  γ-Glu-Val could not be detected during the incubation. 
The concentration of [FL-no: 17.038] in the incubation was based on the presumed intestinal 
concentration after oral consumption of [FL-no: 17.038]-containing food, 15 µM (Flavour Industry, 
2013). 
Hydrolysis by a homogenate of human small intestinal mucosa (XenoTech Co Ltd; no details 
available) at pH 8.0 indicated that [FL-no: 17.038] was rapidly hydrolysed by the homogenate of 
human intestinal mucosa (3.2 mg/ml protein); after 10 minutes, 42 % was hydrolysed, while 21 % was 
present as Val-Gly. After 60 minutes, 97 % was hydrolysed, while 7 % was still present as Val-Gly. 
Very low levels of the γ-Glu-Val dipeptide (less than 1 %) could be detected during the incubation. 
The initial concentration of [FL-no: 17.038] in the incubation was 15 µM (Flavour Industry, 2013).  
In order to assess the capacity of the intestine to hydrolyse the candidate substance [FL-no: 17.038] 
after oral administration in humans to its individual amino acids, the data of Bruyère et al (2010) were 
used These authors estimated that the microsomal protein content of scraped off human intestinal 
mucosa remained constant along the length of the small intestine, at about 1.55 mg/cm intestine 
(Bruyère et al., 2010). Using the data on hydrolysis of the candidate substance [FL-no: 17.038] by the 
microsomal fraction from human small intestinal mucosa (see above), it can be calculated
8
 that at pH 
8.0 the peptide would be very rapidly hydrolysed in vivo after oral administration. It is not clear 
whether the hydrolysing enzymes in vivo, as recovered in the microsomal fraction, are present in the 
membranes at the luminal surface of the mucosal cells (which will be recovered in the microsomal 
fraction) or inside the mucosal cell; in the latter case the peptide would have to be taken up by the cell 
by carriers before it could be hydrolysed.   
In summary, it can be assumed that the candidate substance γ-glutamyl-valyl-glycine [FL-no: 17.038] 
is rapidly hydrolysed to its individual amino acids after oral administration with the food.  
9. Toxicity Data (Appendix F) 
9.1. 28-Day Dietary Administration Systemic Toxicity Study in Rats  
In order to examine the toxicity of the candidate substance γ-glutamyl-valyl-glycine [FL-no: 17.038], 
a 28 days toxicity study according to OECD Guideline 407 was conducted (a GLP study), including 
full histopathology of the high dose group (Okamura, 2010). [FL-no: 17.038] was mixed with basal 
powder diet and given to Sprague-Dawley strain SPF rats [Crl:CD(SD), 10 males and 10 females per 
dose, six weeks of age at the start of administration] by 28-day dietary administration at dose levels of 
100, 300 and 1000 mg/kg bw/day. A control group received the basal powder diet alone in the same 
                                                     
8 See Appendix E for the calculation. 
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manner. The rats were housed individually. The mean intake of [FL-no: 17.038] in each test article 
administration group during the administration period was 114, 336 and 1113 mg/kg bw/day in males 
and 114, 328 and 1124 mg/kg bw/day in females in the 100, 300 and 1000 mg/kg bw/day groups, 
respectively. 
No deaths occurred during the administration period, and there were no changes that were thought to 
be attributable to administration of [FL-no: 17.038] observed in clinical signs, detailed clinical 
observations, manipulative test, grip strength, motor activity, body weights, food consumption, water 
intake, ophthalmology, hematology, necropsy or histopathology in any tissue examined. 
In urinalysis, a tendency toward increase in the number of animals with positive protein was observed 
in males in the 300 and 1000 mg/kg groups, but not in females. However, it was judged to have no 
toxicological significance since there were no changes in the blood chemistry examination suggesting 
damage in kidney function and there were no changes in the (histo-)pathological examinations. None 
of the other 13 urinalysis parameters was changed. 
In blood chemistry examination, no changes were observed except for slight but statistically 
significant decreases (16 %) in urea nitrogen and creatinine in males in the 1000 mg/kg group, which 
were judged to have no toxicological significance since they were not increased but rather decreased 
compared to controls.  
There were no changes in organ weights except for statistically significant lower values (17 - 20 %) in 
the relative and absolute weights of the spleen in females in the 100 and 1000 mg/kg groups. 
However, the changes were within the range of the historical controls of Bozo Research Center Inc.. 
They were judged to have no toxicological significance since hematological and histopathological 
examination of the lymphatic/hematopoietic organs including the spleen showed no changes. 
The No Observed Adverse Effect Level (NOAEL) of [FL-no: 17.038] under the conditions of this 28-
day study was higher than 1000 mg/kg bw/day in both sexes.  
The Panel considered that sub-chronic toxicity studies are not needed for the evaluation of γ-glutamyl-
valyl-glycine [FL-no: 17.038] in the present case as the evaluation is solely based on the ready 
hydrolysis of the tripeptide into the respective amino acids upon digestion. 
10. Exposure Compared to TTC 
Not applicable. 
11. Procedure for Assessment / Safety Assessment  
As the consumption of the single amino acids from which the candidate substance is build is orders of 
magnitude higher than the intake arising from the use as flavouring substance, the Panel decided not to 
carry out the safety assessment according to the Procedure (Appendix A). Instead the below listed 
statements lead to the final conclusion for the candidate substance.  
 The candidate substance [FL-no: 17.038] presents no safety concern with respect to genotoxicity. 
 It can be assumed that the candidate substance [FL-no: 17.038] is rapidly hydrolysed to its 
individual amino acids, L-glutamic acid, L-valine and glycine, after oral intake with the food.  
 Of these endogenous amino acids, two (glycine and L-valine) are evaluated in existing FGE’s 
(FGE.26Rev1 (EFSA, 2008a) and FGE.79 (EFSA, 2008b)). L-glutamic acid was evaluated by the  
JECFA (JECFA no 1420) (JECFA, 2006).  
 To assess the (margin of) safety for the intake of the amino acids released from [FL-no: 17.038] 
the following can be considered. The generally accepted human daily allowance of protein is 700 
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mg/kg bw/day ((Institute of Medicine, 2005): dietary reference intake tables), i.e. 42.000 mg 
protein (60 kg person) in the form of amino acids. The APET estimate for [FL-no: 17.038] adds 
5.5 mg/day in the form of amino acids Gly, Val and Glu. Of this total protein intake, approx. 
6.5%, i.e. 2730 mg, is the essential amino acid L-Valine 
(www.proteinsandproteomics.org/content/free/tables_1/table08.pdf); the intake of valine through 
[FL-no: 17.038] adds approximately 2 mg to this amount. The (minimum) requirement for L-
valine is 10 mg/kg bw/day (WHO, 1985). Thus, the human exposure of these three endogenous 
amino acids through food is orders of magnitude higher than the anticipated levels of exposure 
from their use as flavouring substances derived from γ-glutamyl-valyl-glycine [FL-no: 17.038].  
Therefore, these three substances were not taken through the Procedure and the Panel concluded that 
these substances were not of safety concern at their estimated levels of intake as flavouring substances. 
The Panel therefore also conclude for the candidate substance γ-glutamyl-valyl-glycine [FL-no: 
17.038] that it is not of safety concern at its estimated level of intake as flavouring substance. 
12. Margin of Safety 
Not applicable. 
CONCLUSION 
The Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids of the European 
Food Safety Authority was requested to evaluate one flavouring substance (candidate substance) in the 
Flavouring Group Evaluation 401, using the Procedure in Commission Regulation (EC) No 
1331/2008. 
The candidate substance γ-glutamyl-valyl-glycine [FL-no: 17.038] is a synthetic substance. It has also 
been identified as a natural component in vegetable and animal materials and has been quantitated in 
some unprocessed and processed food. 
According to the applicant the candidate substance γ-glutamyl-valyl-glycine [FL-no: 17.038] is 
intended to be used to modify and balance the total flavour bringing out the middle to afternote and 
adds brothy, creamy flavours similar to that of well-cooked stew.  
The dietary exposure to the candidate substance is calculated to be 92 μg/kg bw/day in a 60 kg adult 
and 231 μg/kg bw/day in a 15 kg three-year old child. In per capita terms, these are 5500 μg/capita/day 
and 3465 μg/capita/day, respectively. Despite the fact that the substance is not intended to be used in 
food categories specifically intended for infants and young children, they will also consume food from 
the general food categories which may contain the substance. However, because the safety assessment 
of the substance is based on exposure to the separate amino acids, the Panel considers this to be of no 
safety concern. 
The highest acute exposure value of 1.26 mg/kg bw derived from the scenario of a 15 kg three year old 
child consuming three portions (3 x 200 x 0.63 = 378 g) of category 12.5 (soups and broths) all of 
which contain the maximum concentration of [FL-no: 17.038]. This is considered not to be of safety 
concern. 
There was no indication of genotoxicity in the bacterial reversion assays, in an in vitro chromosome 
aberration assay and in an in vivo micronucleus test. Based on these data there is no safety concern 
with respect to genotoxicity for the candidate substance. In a 28-day oral study in rats the no observed 
adverse effect level (NOAEL) of [FL-no: 17.038] was 1000 mg/kg bw/day (the highest dose) in both 
sexes. No 90 days study will be required as the evaluation is solely based on the hydrolysis of the 
tripeptide into amino acids. 
Since it can be assumed that the candidate substance [FL-no: 17.038] is rapidly hydrolysed to its 
individual amino acids after oral administration with the food, the Panel based its risk assessment on 
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the hydrolysis products, the three individual amino acids, L-glutamic acid (evaluated by the JECFA, 
JECFA no 1420), L-valine [FL-no: 17.028] (evaluated by the EFSA in FGE.26Rev1) and glycine 
([FL-no: 17.034] (evaluated by the JECFA, JECFA no 1421 and considered by the EFSA in FGE.79). 
The human exposure to these three endogenous amino acids, through food is orders of magnitude 
higher than the anticipated levels of exposure from their use as flavouring substances. Therefore, these 
three substances were not taken through the Procedure. The Panel concluded that the substances were 
not of safety concern at their estimated levels of intake as flavouring substances. 
The specifications for [FL-no: 17.038] are considered adequate according to Commission Regulation 
(EC) no 1334/2008.   
Based on the above considerations, the candidate substance, γ-glutamyl-valyl-glycine [FL-no: 17.038] 
is also not considered to be of safety concern at its estimated level of intake as flavouring substance. 
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APPENDIX  
Appendix A.  Procedure Scheme 
 
Figure A.2 Procedure for Safety Evaluation of Individual Flavouring Substances 
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Appendix B.  Structurally and Metabolically Related Substances 
Hydrolysis products of the candidate substance [FL-no: 17.038] were identified among the flavouring 
substances that have already been evaluated by EFSA or JECFA. These are the amino acids evaluated: 
L-glutamic acid (evaluated by JECFA, JECFA no 1420), L-valine [FL-no: 17.028] (evaluated in 
FGE.26Rev1 (EFSA, 2008a)) and glycine ([FL-no: 17.034] evaluated by JECFA, JECFA no 1421 
(JECFA, 2006) and considered by EFSA in FGE.79 (EFSA; 2008b)). 
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Appendix C.  Use Levels and Exposure Calculations 
Table 4:  Normal and Maximum Occurrence Levels for Sub-Categories of Foods and Beverages 
CODE
X code 
Food categories § Standard 
portions* (g) 
Occurrence level as 
added flavouring (mg/kg) 
Occurrence level from 
other sources @ (mg/kg) 
Combined occurrence 
level from all sources # 
(mg/kg) 
Normal Maximum Normal$ Maximum Normal Maximum 
01.1 Milk and dairy-based drinks 200 15 45   15 45 
01.2 
Fermented and renneted milk products (plain), excluding food 
category 01.1.2 (dairy-based drinks) 
200 15 45   15 45 
01.3 Condensed milk and analogues (plain) 70 20 50   20 50 
01.4 Cream (plain) and the like 15 20 50   20 50 
01.5 Milk powder and cream powder and powder analogues (plain) 30 15 45   15 45 
01.6 Cheese and analogues 40   0.47 0.59 0.47 0.59 
01.7 Dairy-based desserts (e.g., pudding, fruit or flavoured yoghurt) 125 15 45   15 45 
01.8 Whey and whey products, excluding whey cheeses 200       
02.1 Fats and oils essentially free from water 15 30 60   30 60 
02.2 Fat emulsions mainly of type water-in-oil 15 30 60   30 60 
02.3 
Fat emulsions mainly of type water-in-oil, including mixed and/or 
flavoured products based on fat emulsions 
15 30 60   30 60 
02.4 
Fat-based desserts excluding dairy-based dessert products of category 
1.7 
50 15 45   15 45 
03.0 Edible ices, including sherbet and sorbet 50       
04.1.1 Fresh fruit 140       
04.1.2 Processed fruit 125       
04.1.2.5 Jams, jellies, marmalades 30       
04.2.1 
Fresh vegetables (including mushrooms and fungi, roots and tubers, 
pulses and legumes, and aloe vera), seaweed, and nut and seed 
200       
04.2.2 
Processed vegetables (including mushrooms and fungi, roots and 
tubers, pulses and legumes, and aloe vera), seaweed, and nut and 
seed purees and spreads (e.g. peanut butter) and nuts and seeds 
200       
04.2.2.5 
Vegetables (including mushrooms and fungi, roots and tubers, pulses 
and legumes, and aloe vera), seaweed, and nut and seed purees and 
spreads (e.g. peanut butter) 
30       
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CODE
X code 
Food categories § Standard 
portions* (g) 
Occurrence level as 
added flavouring (mg/kg) 
Occurrence level from 
other sources @ (mg/kg) 
Combined occurrence 
level from all sources # 
(mg/kg) 
Normal Maximum Normal$ Maximum Normal Maximum 
05.1 
Cocoa products and chocolate products, including imitations and 
chocolate substitutes 
40 30 60   30 60 
05.1.3 Cocoa-based spreads, including fillings 30       
05.2 
Confectionery, including hard and soft candy, nougats, etc., other 
than 05.1, 05.3 and 05.4 
30       
05.3 Chewing gum 3       
05.4 
Decorations (e.g. for fine bakery wares), toppings (non-fruit) and 
sweet sauces 
35       
06.1 Whole, broken or flaked grain, including rice 200       
06.2 Flours and starches (including soya bean powder) 30       
06.3 Breakfast cereals, including rolled oats 30 80 160   80 160 
06.4 
Pastas and noodles and like products (e.g. rice paper, rice vermicelli, 
soya bean pastas and noodles) 
200       
06.5 Cereal and starch based desserts (e.g. rice pudding, tapioca pudding) 200       
06.6 Batters (e.g. for breading or batters for fish or poultry) 30       
06.7 
Pre-cooked or processed rice products, including rice cakes (Oriental 
type only) 
200       
06.8 
Soya bean products (excluding soya bean products of food category 
12.9 and fermented soya bean products of food category 12.10) 
100       
07.1 Bread and ordinary bakery wares 50       
07.2 Fine bakery wares (sweet, salty, savoury) and mixes 80 30 60   30 60 
08.1 Fresh meat, poultry and game 200       
08.2 Processed meat, poultry and game products in whole pieces or cuts 100 15 45 0.85 0.85 15.85 45.85 
08.3 Processed comminute meat, poultry and game products 100 15 45   15 45 
08.4 Edible casings (e.g. sausage casings) 1 15 45   15 45 
09.1.1 Fresh fish 200       
09.1.2 Fresh molluscs, crustaceans and echinoderms 200   0.5 0.77 0.5 0.77 
09.2 
Processed fish and fish products, including molluscs, crustaceans and 
echinoderms 
100       
09.3 Semi-preserved fish and fish products, including molluscs, 100       
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CODE
X code 
Food categories § Standard 
portions* (g) 
Occurrence level as 
added flavouring (mg/kg) 
Occurrence level from 
other sources @ (mg/kg) 
Combined occurrence 
level from all sources # 
(mg/kg) 
Normal Maximum Normal$ Maximum Normal Maximum 
crustaceans and echinoderms 
09.4 
Fully preserved, including canned or fermented, fish and fish 
products, including molluscs, crustaceans and echinoderms 
100   0.1 0.17 0.1 0.17 
10.1 Fresh eggs 100       
10.2 Egg products 100       
10.3 Preserved eggs, including alkaline. salted and canned eggs 100       
10.4 Egg-based desserts (e.g. custard) 125       
11.1 Refined and raw sugar 10       
11.2 Brown sugar excluding products of food category 11.1 10       
11.3 
Sugar solutions and syrups, and (partially) inverted sugars, including 
molasses and treacle, excluding products of food category 11.1.3 
(soft white sugar, soft brown sugar, glucose syrup, dried glucose 
syrup, raw cane sugar) 
30       
11.4 Other sugars and syrups (e.g. xylose, maple syrup, sugar toppings) 30       
11.5 Honey 15       
11.6 
Table-top sweeteners, including those containing high-intensity 
sweeteners 
1       
12.1 Salt and salt substitutes 1       
12.2 
Herbs, spices, seasonings and condiments (e.g. seasoning for instant 
noodles) 
1 80 160 4.45 11.14 84.45 171.14 
12.3 Vinegars 15       
12.4 Mustards 15       
12.5 Soups and broths 200 20 50   20 50 
12.6 Sauces and like products 30 20 50   20 50 
12.7.a 
Salads 120 g (e.g. macaroni salad, potato salad) excluding cocoa- and 
nut-based spreads of food categories 
120       
12.7.b 
Sandwich spreads (20 g), excluding cocoa- and nut-based spreads of 
food categories 
20       
12.8 Yeast and like products 1 15 45   15 45 
12.9 Soybean-based seasonings and condiments 15       
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CODE
X code 
Food categories § Standard 
portions* (g) 
Occurrence level as 
added flavouring (mg/kg) 
Occurrence level from 
other sources @ (mg/kg) 
Combined occurrence 
level from all sources # 
(mg/kg) 
Normal Maximum Normal$ Maximum Normal Maximum 
12.9.2 Soybean sauce 15       
12.9.3 Fermented soybean sauce 15       
12.9.1 Fermented soya bean products (e.g. miso) 40       
12.10 Protein products other than from soybeans 15   3.93 5.78 3.93 5.78 
13.2. a 
Complementary foods for infants and young children: Dry instant 
cereals (with or without milk), including pasta 
110       
13.2. b 
Complementary foods for infants and young children: Meat based or 
fish based dinner 
170       
13.2. c 
Complementary foods for infants and young children: Dairy based 
dessert 
110       
13.2. d 
Complementary foods for infants and young children: Vegetables, 
potatoes, broth, soups,  pulses 
170       
13.2. e 
Complementary foods for infants and young children: Biscuits and 
cookies 
20       
13.2. f Complementary foods for infants and young children: Fruit purée 110       
13.2. g Complementary foods for infants and young children: Fruit juice 120       
13.2. h Milk for young children 200       
13.3 
Dietetic foods intended for special medical purposes (excluding food 
products of category 13.1 “Infant formulae, follow-up formulae and 
other formulae for special medical purposes for infants”) 
200       
13.4¤ Dietetic formulae for slimming purposes and weight reduction 200       
13.5 
Dietetic foods (e.g. supplementary foods for dietary use), excluding 
products of food categories 13.1 (Infant formulae, follow-up 
formulae and other formulae for special medical purposes for 
infants”), 13.2–13.4 and 13.6 
200       
13.6 Food supplements 5       
14.1a Coffee powder 12       
14.1b Drinks mix powders 30       
14.1c Other non-alcoholic (“soft”) beverages (expressed as liquid) 300 5 15   5 15 
14.2.1¤ Beer and malt beverages 300   0.13 0.18 0.13 0.18 
14.2.2¤ Cider and perry 300       
Flavouring Group Evaluation 401 
 
 
25 EFSA Journal 2014;12(4):3625 
CODE
X code 
Food categories § Standard 
portions* (g) 
Occurrence level as 
added flavouring (mg/kg) 
Occurrence level from 
other sources @ (mg/kg) 
Combined occurrence 
level from all sources # 
(mg/kg) 
Normal Maximum Normal$ Maximum Normal Maximum 
14.2.3¤ Grape wines 150       
14.2.4¤ Wines (other than grape) 150       
14.2.5¤ Mead 150       
14.2.6¤ Distilled spirituous beverages containing more than 15 % alcohol 30       
14.2.7¤ 
Aromatized alcoholic beverages (e.g., beer, wine and spirituous 
cooler-type beverages, low alcoholic refreshers) 
300       
15.1 
Snacks, potato-, cereal-, flour- or starch-based (from roots and tubers, 
pulses and legumes) 
30 80 160   80 160 
15.2 
Processed nuts, including coated nuts and nut mixtures (with e.g. 
dried fruit) 
30       
15.3 Snacks – fish based 30       
16.0 
Composite foods (e.g. casseroles, meat pies, mincemeat) – foods that 
could not be placed in categories 01–15 
300       
 
§ Most of the categories reported are the sub-categories of Codex GSFA (General Standard for Food Additives, available at http://www.codexalimentarius.net/gsfaonline/CXS_192e.pdf) used by 
the JECFA in the SPET technique (FAO/WHO, 2008). In the case of category 13.2 (complementary foods for infants and young children), further refined categories have been created so that a 
specific assessment of dietary exposure can be performed in young children.  
* In case of foods marketed as powder or as concentrates, occurrence levels must be reported for the reconstituted product, considering the instructions reported on the product label or one of the 
standard dilution factors established by the JECFA (FAO/WHO 2008):  
- 1/25 for powder used to prepare water-based drinks such as coffee, containing no additional ingredients,  
- 1/10 for powder used to prepare water-based drinks containing additional ingredients such as sugars (ice tea, squashes, etc.),  
- 1/7 for powder used to prepare milk, soups and puddings,  
- 1/3 for condensed milk.  
$ In order to estimate normal values in each category, only foods and beverages in which the substance is present in significant amount will be considered (e.g. for the category “Fresh fruit” 
04.1.1., the normal concentration will be the median concentration observed in all kinds of fruit where the flavouring substance is known to occur).  
# The normal and maximum combined occurrence levels of the substance will be assessed by the applicant either by adding up occurrence levels from added use to that from other sources or by 
expert judgment based on the likelihood of their concomitant presence. This will be done both for normal use levels and for maximum use levels. 
@ As natural constituent and/or developed during the processing and/or as carry over resulting from their use in animal feed.  
¤The sub-categories 14.2.1, 14.2.2, 14.2.3, 14.2.4, 14.2.5, 14.2.6 and 14.2.7 (“Alcoholic beverages”) and the sub-category 13.4 (“Dietetic formulae for slimming purposes and weight reduction”) 
are a priori not consumed by children. 
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DIETARY EXPOSURE TO [FL-NO: 17.038] FROM THE CONSUMPTION OF FLAVOURED FOODS AND BEVERAGES IN ADULTS AND CHILDREN  
Chronic Dietary Exposure 
ADULTS (“Added Portions Exposure Technique” [APET]9).  
On the Basis of Normal Occurrence Level from Added Flavourings  
Food sub-categories resulting in the highest potential dietary exposure:  
Beverage: The maximum intake will be from category 14.1 (Non-alcoholic (“soft”) beverages). The normal combined occurrence level of 5 mg/kg in of 300 g 
of non-alcoholic beverages gives an intake of 1500 μg/person per day.  
Solid Food: The maximum intake will be from category 12.5 (Soups and broths). The normal combined occurrence level of 20 mg/kg in 200 g of soups and 
broths gives an intake of 4000 μg/person per day.  
Chronic APET: 5500 μg/person per day (92 μg/kg bw per day for a 60 kg person).  
CHILDREN (3-year old child of 15 kg body weight)  
Food sub-categories resulting in the highest potential dietary exposure:  
Beverage: The maximum intake will be from category 14.1 (Non-alcoholic (“soft”) beverages). The normal combined occurrence level of 5 mg/kg in of 300 g 
of non-alcoholic beverages gives an intake of 945 μg/child per day (5 mg/kg x 300 g x 0.63).  
Solid Food: The maximum intake will be from category 12.5 (Soups and broths). The normal combined occurrence of 20 mg/kg in 200 g of soups and broths 
gives an intake of 2520 μg/child per day (20 mg/kg x 200 g x 0.63).  
Chronic APET
10: 3465 μg/child per day (231 μg/kg bw per day for a 15 kg child). 
Conclusion  
The chronic APET values are 92 μg/kg bw per day for 60 kg adults and 231 μg/kg bw per day for 15 kg child. In terms of per kg bw, the children value of 
3465 μg/day is the higher.  
                                                     
9  The APET has been calculated based on the occurrence levels in the food sub-categories reported in the above Table, with  
 the exclusion of categories 13.2 (complementary foods for infants and young children). 
10  Excluding sub-categories 13.4, 14.2.1, 14.2.2, 14.2.3, 14.2.4, 14.2.5, 14.2.6 and 14.2.7. Standard portion sizes for children  
 are obtained by multiplying the adult standard portion sizes by a factor of 0.63. 
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INFANTS AND YOUNG CHILDREN 
According to the Applicant [FL-no: 17.038] will not be used in any of the the food categories 13.2a – 13.2h (complementary foods for infants and young 
children).  
Conclusion  
No exposure to [FL-no: 17.038] is expected in any food item for infants and young children (< 3years of age).  
Acute Dietary Exposure 
ADULTS 
The highest acute intake is assumed to result from the consumption of three portions
11
 of category 12.5 (soups and broths) containing a maximum 
concentration of 50 mg/kg of [FL-no: 17.038]. This gives a value of 3 x 200 g x 50 mg/kg = 30 mg/person = 500 μg/kg for a 60 kg person.  
CHILDREN
12
 
The highest acute intake is assumed to result from the consumption of three portions (3 x 200 g x 0.63 = 378 g) of category 12.5 (soups and broths) containing 
a maximum concentration of 50 mg/kg of [FL-no: 17.038]. This gives a value of 378 g x 50 mg/kg = 18.9 mg/child = 1260 μg/kg for a 15 kg child.  
INFANTS AND YOUNG CHILDREN (< 3 YRS): No intentional consumption is intended.  
Conclusion 
The highest
13
 acute APET value is 1260 μg/kg bw derived from the scenario of a 15 kg three year old child consuming three portions (3 x 200 g x 0.63 = 378 
g) of food category 12.5 (soups and broths) all of which contain the maximum concentration of [FL-no: 17.038]. 
Cumulative Dietary Exposure to [FL-no: 17.038]  
The candidate substance γ-glutamyl-valyl-glycine [FL-no: 17.038] is considered to be rapidly hydrolysed before absorption to the three endogenous amino 
acids, L-glutamic acid (evaluated by JECFA (JECFA, 2006), JECFA no 1420), L-valine [FL-no: 17.028] (evaluated by EFSA (EFSA, 2008a) and glycine 
([FL-no: 17.034] evaluated by JECFA, JECFA no 1421 (JECFA, 2006) and considered by EFSA in FGE.79 (EFSA, 2008b)). The exposure of these amino 
                                                     
11  EFSA Journal 2010; 8(6):1623, Guidance on data submission for flavourings evaluation: In both adults and 3 year-old  
 children, the acute exposure is represented by the consumption of three portions of either a solid food or a beverage,  
 containing the flavouring substance at its maximum occurrence levels. 
12  Based on the same considerations as for adults but using the special factors used for chronic exposure to infants. 
13  The highest value obtained among adults and children of all ages. 
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acids through food is orders of magnitude higher than the anticipated level of exposure from the use of the candidate substance γ-glutamyl-valyl-glycine [FL-
no: 17.038] as a flavouring substance.  
It is therefore not considered applicable to calculate the cumulative dietary exposure.  
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Appendix D.  Genotoxicity 
Table 5:  Summary of in vitro genotoxicity studies 
FL-no 
JECFA-no 
Union list name / 
test material 
Test System Test Object Concentration Result Reference Comments 
17.038 
2123 
γ-Glutamyl-valyl-
glycine 
Ames test S.typhimuriun TA98, TA100, 
TA1535, TA1537 
E.coli WP2 uvrA 
Up to 5 mg/plate  
(with and without metabolic 
activation S9-mix) 
Negative Oguma, 2010  Test in according with OECD 
Guideline 471 and GLP. 
Chromosome aberration 
test 
Chinese hamster lung fibroblast 
(CHL/IU) cells 
Up to 3100 μg/mL  Negative Sono, 2010 Test in accordance with 
OECD Guideline 473 test 
and GLP.  
 
Table 6:  Summary of in vivo genotoxicity studies 
FL-no 
JECFA-no 
Union list name / 
test material 
Test System Test Object Route Dose  Result Reference Comments 
17.038 
2123 
γ-Glutamyl-valyl-
glycine 
Micronucleus test Mice Oral  Up to 2000 mg/kg bw Negative Ishii, 2010 Test in accordance with OECD 
Guideline 474 and GLP.  
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Appendix E.  Metabolism 
According to the applicant, the anticipated usual use level of  γ-glutamyl-valyl-glycine [FL-no: 
17.038] in food is approximately 20 ppm or 66 μM. The applicant assumes a concentration of 5 mg/kg 
or 16 μM in the intestinal fluid released from the stomach.  
In the incubation with a human intestinal microsomal preparation, after 10 minutes (at pH 8.0), 97 % 
of the tripeptide had been hydrolysed to the dipeptide Val-Gly; after 60 minutes, 60 % had been 
completely hydrolysed (Flavour Industry, 2013).  
The concentration of (human) intestinal microsomal protein in the incubation was 8 mg/ml; the 
microsomal protein content of human intestine is 1.55 per cm (Bruyère et al., 2010). Thus, 8 mg of 
microsomal protein corresponds to 8/1.55, i.e. approximately five cm (of the total of seven meters) of 
human small intestine. 
During 10 minutes presence of the intestinal fluid in five cm of small intestine over 90 % would be 
expected to be hydrolysed to the dipeptide. Therefore, the tripeptide will disappear very rapidly 
(within a few minutes), once in the small intestine. Complete hydrolysis would take longer: in the 
same five cm during 60 minutes, 60 % would be completely hydrolysed. However, as the intestinal 
fluid passes through the small intestine more microsomal protein would become recruited, so that over 
a length of 50 cm a 60 % complete hydrolysis of the dipeptide would only take six minutes. As the 
intestinal fluid moves through the small intestine, the hydrolysis would increase progressively till 
virtual completeness.   
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Table 7:  Summary of the Procedure for Evaluation of Individual Flavouring Substances 
FL-no EU Register 
name 
Structural 
formula 
JECFA no 
CAS no 
Procedure 
pathway 
(A or B)(a) 
Structural 
class 
Chronic APET 
µg/person/day 
(Adult or Child)(b) 
Procedure step Toxicological data 
required 
EFSA comments 
[17.038] γ-glutamyl-
valyl-glycine 
* - 
38837-70-6 
** I 3465 - - - 
(a): Data available to demonstrate that metabolites are to be considered innocuous? Yes: A; No: B 
(b): The highest chronic APET value among adults and children expressed in µg/person/day 
 
* 
H
N
N
H
OH
O
HO
O O
ONH2
 
 
** The human exposure of the three endogenous amino acids, L-glutamic acid (evaluated by JECFA, JECFA no 1420), L-valine [FL-no: 17.028] and glycine 
through food is orders of magnitude higher than the anticipated levels of exposure from their use as flavouring substances. Therefore, these three substances 
are not taken through the Procedure. However, the Panel concluded that the substances were not of safety concern at their estimated levels of intake as 
flavouring substances. 
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Table 8:  Summary of Evaluation of Metabolism Products from the Flavouring Substance 
FL-no 
JECFA-no 
Name 
   
Structural formula Estimated amount 
MSDI (EU) µg/capita/day  
EFSA status Cramer class EFSA Comments 
- 
1420 
L-glutamic acid 
HO OH
NH2
OO
 
267* No evaluation as flavouring 
substance 
III L-glutamic acid is not 
used as a flavour in the 
EU. JECFA has evaluated 
the substance: No safety 
concern at the estimated 
level of intake as a 
flavouring substance. 
17.028 
 
L-Valine 
NH2
O
OH
 
18 No safety concern at the 
estimated level of intake as a 
flavouring substance. 
I  
17.034 
1421 
Glycine 
 
135 No safety concern at the 
estimated level of intake as a 
flavouring substance. 
III  
 
*The 267 µg/capita/day originates from the JECFA figure of 313 µg/capita/day. JECFA assume that EU population is 320 x 106, EFSA use the figure 375 x 106. Therefore is the estimated 
amount (MSDI) in EU calculated to be: 313 µg/capita/day x (320 x 106 / 375 x 106) = 267 µg/capita/day.     
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Appendix F.  Toxicity 
Acute Oral Toxicity Study in Rats  
None were submitted. 
28-Day Range-Finding Systemic Dietary Toxicity Study in Rats  
See section 9.1 and table 9. 
90-Day Dietary Administration Systemic Toxicity Study in Rats  
None were submitted.  
 
Table 9:  Summary of Toxicity studies 
FL-no 
JECFA-
no 
Union list 
name / test 
material 
Species; 
Sex 
No/group 
Route of 
administration 
Dose level 
Mg/kg 
bw/da
y 
Duration LD50 / 
NOAEL / 
BMDL 
(mg/kg 
bw/day) 
Reference Comments 
17.038 
2123 
γ-
Glutamyl-
valyl-
glycine 
Sprague-
Dawley 
rats: 10 
M/10 
F/dose level  
 
Dietary Calculated 
mean intake 
in each 
group were 
M: 114, 336 
and 1113 
mg/kg bw 
F: 114, 328 
and 1124 
mg/kg bw 
28-days NOAEL: 
> 1000 
mg/ kg 
bw/ day 
Okamura 
T, 2010 
Range finding 
study. 
The 
administrated 
dose levels were 
100, 300 and 
1000 mg/ kg 
bw/day. 
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ABBREVIATIONS 
APET  Added Portions Exposure Technique 
BW  Body Weight 
CAS  Chemical Abstract Service 
CEF Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids 
Chemical Abstract Service 
CoE  Council of Europe 
EC  European Commission 
EFSA  The European Food Safety Authority 
EU  European Union 
FAO  Food and Agriculture Organization of the United Nations  
FEMA  Flavor and Extract Manufacturers Association 
FGE  Flavouring Group Evaluation  
FLAVIS (FL) Flavour Information System (database) 
GC  Gas Chromatography 
GLP  Good Laboratory Practice 
GMO  Genetically Modified Organisms 
HPLC  High Performance Liquid Chromatography 
ID   Identity 
IOFI  International Organization of the Flavour Industry 
IR   Infrared spectroscopy 
JECFA  The Joint FAO/WHO Expert Committee on Food Additives 
LC  Liquid Chromatography 
MS  Mass spectrometry 
MSDI  Maximised Survey-derived Daily Intake 
NMR  Nuclear Magnetic Resonance 
No  Number 
NOAEL No Observed Adverse Effect Level 
OECD  Organisation for Economic Co-operation and Development 
RH  Relative Humidity 
S9-MIX A metabolic activation system with rat-liver microsome fraction plus cofactors 
SCF  Scientific Committee on Food 
UV  Ultraviolet 
WHO  World Health Organisation 
 
